-
Aravant Sickle Cell Therapy Gets FDA Rare Pediatric Disease Designation
The FDA made ARU-1801, Aruvant’s experimental sickle cell therapy, eligible for faster review under the rare pediatric disease program. Read more about it here.
What did you think of this news?
Sorry, there were no replies found.
Log in to reply.